Payment overview · 2025
General Payments
$627.49
31 reported records · 11 companies
Healthcare provider profile · identity verified
Seshasree Marupudi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHENANDOAH, TX · NPI 1992998645
Verified facts
What the public records show
CMS Open Payments records show Seshasree Marupudi, MD received $627.49 in general payments during 2025 across 31 reported records.
Lilly USA, LLC accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $182.72 | 29.1% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.52 | 13.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.95 | 12.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.55 | 10.8% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $55.12 | 8.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.77 | 6.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.30 | 5.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.53 | 3.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $21.85 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.68 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.50 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $627.49 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $120.39 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $89.17 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $78.95 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.50 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $69.65 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.55 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $55.12 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $9.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 115 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 498 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 108 |
| Losartan Potassium | Losartan Potassium | 314 | 103 |
| Gabapentin | Gabapentin | 227 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 207 | 83 |
| Montelukast Sodium | Montelukast Sodium | 179 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 59 |
| Metformin Hcl | Metformin Hcl | 172 | 54 |
| Trazodone Hcl | Trazodone Hcl | 139 | 55 |
| Cefdinir | Cefdinir | 135 | 105 |
| Furosemide | Furosemide | 125 | 47 |
| Memantine Hcl | Memantine Hcl | 124 | 41 |
| Carvedilol | Carvedilol | 117 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 56 |
| Jardiance | Empagliflozin | 115 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 48 |
| Ozempic | Semaglutide | 114 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 83 |
| Sertraline Hcl | Sertraline Hcl | 91 | 28 |
| Lisinopril | Lisinopril | 89 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 61 |
| Mounjaro | Tirzepatide | 85 | 21 |
| Methylprednisolone | Methylprednisolone | 84 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 35 |
| Simvastatin | Simvastatin | 79 | 22 |
| Allopurinol | Allopurinol | 71 | 19 |
| Eliquis | Apixaban | 71 | 26 |
| Spironolactone | Spironolactone | 68 | 26 |
| Potassium Chloride | Potassium Chloride | 67 | 30 |
| Nifedipine Er | Nifedipine | 66 | 19 |
| Alendronate Sodium | Alendronate Sodium | 64 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 23 |
| Bupropion Xl | Bupropion Hcl | 54 | 21 |
| Valsartan | Valsartan | 54 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 30 |
| Synthroid | Levothyroxine Sodium | 52 | 13 |
| Famotidine | Famotidine | 51 | 23 |
| Meloxicam | Meloxicam | 51 | 26 |
| Valacyclovir | Valacyclovir Hcl | 50 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 40 |
| Glipizide | Glipizide | 48 | 15 |
| Azithromycin | Azithromycin | 46 | 41 |
| Farxiga | Dapagliflozin Propanediol | 45 | 12 |
| Prednisone | Prednisone | 44 | 31 |
| Estradiol | Estradiol | 43 | 22 |
| Omeprazole | Omeprazole | 42 | 14 |
| Donepezil Hcl | Donepezil Hcl | 41 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 40 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 14 |
| Pregabalin | Pregabalin | 37 | 16 |
| Ezetimibe | Ezetimibe | 36 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 12 |
| Buspirone Hcl | Buspirone Hcl | 33 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 19 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 22 |
| Azelastine Hcl | Azelastine Hcl | 25 | 16 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 12 |
| Atenolol | Atenolol | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 14 |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Primidone | Primidone | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $627.49 · 31 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, XIFAXAN, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error